|
|
||||||||
PET Department (Drs. Khan, Antonini, and Leenders), Paul Scherrer Institute, Villigen, Switzerland; the Department of Neurology (Drs. Parkes and Dahlitz), University of London, United Kingdom; Neurology Hospital Hephata (Dr. Meier-Ewert), Treysa, Germany; and the Department of Neurology (Dr. Weindl), University of Miinchen, Munich, Germany.
We investigated in vivo D2 receptor binding using 11C-raclopride and PET in the striatum of 17 subjects with the narcoleptic syndrome. Putamen and caudate nucleus 11C-raclopride uptake was comparable in the total patient group and controls, and the tracer uptake was similar in the HLA-DR2-positive (n = 12) and HLA-DR2-negative (n = 5) narcoleptic subjects. There was a significant increase in 11C-raclopride uptake in the putamen of narcoleptic subjects older than 31 years (n = 11) when compared with age-matched controls (n = 15). There was no evidence of involvement of the striatal D2 dopaminergic neurotransmitter system in the basic pathophysiology of the narcoleptic syndrome despite an age-related increase in putaminal 11C-raclopride uptake.
Address correspondence and reprint requests to Dr. K.L. Leenders, Paul Scherrer Institute, CH-5232 Villigen, Switzerland.
Supported in part by the Swiss National Research Foundation, grant no. 31-30079.90.
Received February 16, 1994. Accepted in final form May 11, 1994.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |